NewcelX Emerges: A Major Merger in Biotechnology Industry

On October 30, 2025, a pivotal event in the biotechnology sector was recorded with the successful merger of NLS Pharmaceutics Ltd. and Kadimastem Ltd., leading to the establishment of NewcelX Ltd. This merger aligns closely with a previously announced agreement, known as the Merger Agreement, which took effect on the same day. Following the conclusion of this transaction, the newly formed entity, NewcelX, will begin trading on the Nasdaq Capital Market under the ticker symbol "NCEL" from October 31, 2025.

As a direct result of this Merger, the holders of Kadimastem ordinary shares were granted 0.706 shares of NewcelX common stock for each Kadimastem share they owned. This exchange ratio compensates for a reverse share split, ensuring that the financial frameworks of both entities align post-merger. NewcelX now has about 4,558,378 common shares outstanding, alongside other forms of securities and contingent value rights for shareholders.

Professor Michel Revel, Chief Scientific Officer of NewcelX, reflected on the merger by highlighting the unification of groundbreaking research in regenerative medicine under a single global umbrella. His statement underscores the therapeutic prospects for patients dealing with complex conditions like amyotrophic lateral sclerosis (ALS) and Type 1 diabetes. He expressed confidence that this merger positions NewcelX to fulfill its promise of advancing therapies that can significantly improve patient lives.

Ronen Twito, also the Executive Chairman and CEO of NewcelX, echoed this sentiment during the post-merger announcements. He acknowledged the decision as an important milestone—one that manifests the trust shareholders and investors have in the company. Twito expressed gratitude for the unwavering support from stakeholders and emphasized preparations for their upcoming Phase 2a clinical trial of AstroRx™, specifically aimed at ALS patients. Additionally, he mentioned the objective to further the development of IsletRx™, a treatment designed for Type 1 diabetes that may not rely on lifelong immunotherapy.

NewcelX, based in Zurich, Switzerland, plans to leverage the combined expertise from both legacy companies to accelerate the research and development of regenerative therapies. Among the leadership team guiding this initiative include notable figures such as Prof. Michel Revel (Chief Scientific Officer), Alexander Zwyer (Director), and Kfir Molakandov, PhD (Vice President of Research and Development).

Amidst the promising outlook, both the management and stakeholders acknowledge the inherent uncertainties in navigating the biotech landscape. Several factors could hinder NewcelX’s immediate ambitions. These range from unforeseen costs and regulatory hurdles surrounding clinical trials to the dynamic nature of market demands and potentially evolving technological landscapes. Nevertheless, the merger showcases a significant ambition for NewcelX to fulfill its responsibilities in the biotech industry and respond to pressing health challenges.

As NewcelX commences trading, all eyes will be on how quickly the newly formed entity can harness its research capabilities into viable treatments. The healthcare community and investors alike are hopeful that this merger will contribute towards innovative solutions benefiting those afflicted with debilitating health conditions. By uniting the forces of NLS Pharmaceutics Ltd. and Kadimastem Ltd., NewcelX could very well lead the charge in breakthroughs that redefine treatment paradigms for neurodegenerative and metabolic diseases.

In conclusion, the establishment of NewcelX Ltd. is anticipated to set forth transformative changes that may enhance lives profoundly while reflecting the remarkable strides being made in science and healthcare.